We develop zero-shot AI for oncology. Our models are rooted in cancer evolutionary biology and the tumor microenvironment, predicting outcomes and treatment response from routine histology slides. We’ve completed blinded pan-cancer validation across 14+ phase II/III trials and 30,000+ patients, all on a single model, without retraining or fine-tuning. Our tests are available today from our CAP-accredited CLIA lab in the Texas Medical Center.